SEC Company Response from KALA BIO, Inc. (KALA) (CIK 0001479419) (KALA) — Aug 23, 2018
KALA BIO, Inc. (KALA) (CIK 0001479419)
Date: Aug. 23, 2018 · CIK: 0001479419 · Accession: 0001558370-18-007195
AI Filing Summary & Sentiment
Reasoning
Letter
Re:
KALA_Current_Folio_Corresp 823
August 23, 2018
VIA EDGAR SUBMISSION
Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549
Attention:
Irene Paik
Mary Beth Breslin
Kala Pharmaceuticals, Inc.
Registration Statement on Form S‑3
File No. 333‑226748
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kala Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S‑3 (File No. 333‑226748), so that it may become effective at 3:00 p.m., Eastern time, on August 27, 2018, or as soon as practicable thereafter.
Very truly yours,
By:
Show Raw Text
CORRESP 1 filename1.htm KALA_Current_Folio_Corresp 823 August 23, 2018 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Irene Paik Mary Beth Breslin Re: Kala Pharmaceuticals, Inc. Registration Statement on Form S‑3 File No. 333‑226748 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kala Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S‑3 (File No. 333‑226748), so that it may become effective at 3:00 p.m., Eastern time, on August 27, 2018, or as soon as practicable thereafter. Very truly yours, By: /s/ Eric Trachtenberg Eric Trachtenberg General Counsel, Chief Compliance Officer and Corporate Secretary